Chemotherapy News and Research RSS Feed - Chemotherapy News and Research

Chemotherapy, in its most general sense, is the treatment of disease by chemicals especially by killing micro-organisms or cancerous cells. In popular usage, it refers to antineoplastic drugs used to treat cancer or the combination of these drugs into a cytotoxic standardized treatment regimen.
Experimental drug may help fight cervical cancer

Experimental drug may help fight cervical cancer

University of Leicester academic leads study into effects of cediranib drug in chemotherapy treatment of cervical cancer. [More]
Novel approach may help detect invasive aspergillosis

Novel approach may help detect invasive aspergillosis

Many different microbes can cause pneumonia, and treatment may be delayed or off target if doctors cannot tell which bug is the culprit. A novel approach—analyzing a patient's breath for key chemical compounds made by the infecting microbe—may help detect invasive aspergillosis, a fungal infection that is a leading cause of mortality in patients with compromised immune systems, according to a proof-of-concept study now online in Clinical Infectious Diseases. [More]
Six platinum cycles no better than four for advanced NSCLC

Six platinum cycles no better than four for advanced NSCLC

Six cycles of adjuvant platinum-based chemotherapy is no better than three or four cycles for patients with advanced non-small-cell lung cancer, meta-analysis results suggests. [More]
Novel way for treating non-cardiac chest pain due to esophageal hypersensitivity

Novel way for treating non-cardiac chest pain due to esophageal hypersensitivity

Chest pain doesn't necessarily come from the heart. An estimated 200,000 Americans each year experience non-cardiac chest pain, which in addition to pain can involve painful swallowing, discomfort and anxiety. Non-cardiac chest pain can be frightening for patients and result in visits to the emergency room because the painful symptoms, while often originating in the esophagus, can mimic a heart attack. [More]
Biomarker test available for breast cancer, but remains unclear for patients with intermediate risk of recurrence

Biomarker test available for breast cancer, but remains unclear for patients with intermediate risk of recurrence

To make a decision for or against adjuvant chemotherapy, a test to measure the concentrations of the biomarkers uPA and PAI-1 in the tumour tissue is available for breast cancer patients. [More]
New study reveals how cancer becomes drug resistant over time

New study reveals how cancer becomes drug resistant over time

Like a colony of bacteria or species of animals, cancer cells within a tumor must evolve to survive. A dose of chemotherapy may kill hundreds of thousands of cancer cells, for example, but a single cell with a unique mutation can survive and quickly generate a new batch of drug-resistant cells, making cancer hard to combat. [More]
Van Andel Research Institute commits $7.5M to support epigenetic therapy in cancer treatment

Van Andel Research Institute commits $7.5M to support epigenetic therapy in cancer treatment

The work of one of the Stand Up To Cancer (SU2C) inaugural Dream Teams, launched in 2009 to focus on epigenetic therapy in cancer treatment, will continue with the commitment of $7.5 million from Van Andel Research Institute (VARI). [More]
Genetic changes in blood cells of older people linked to lymphoma, leukemia

Genetic changes in blood cells of older people linked to lymphoma, leukemia

At least 2 percent of people over age 40 and 5 percent of people over 70 have mutations linked to leukemia and lymphoma in their blood cells, according to new research at Washington University School of Medicine in St. Louis. [More]
Statistical analysis shows stage of breast cancer predicts treatment choice

Statistical analysis shows stage of breast cancer predicts treatment choice

Why did 43 percent of South Dakota women diagnosed with early-stage breast cancer surveyed choose mastectomy rather than lumpectomy? [More]
Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers identify novel method to develop personalized vaccines for ovarian cancer

Researchers at the University of Connecticut have found a new way to identify protein mutations in cancer cells. The novel method is being used to develop personalized vaccines to treat patients with ovarian cancer. [More]
Scientists combine new type of nanoparticle with photodynamic therapy to kill cancer cells

Scientists combine new type of nanoparticle with photodynamic therapy to kill cancer cells

An international group of scientists led by Gang Han, PhD, at the University of Massachusetts Medical School, has combined a new type of nanoparticle with an FDA-approved photodynamic therapy to effectively kill deep-set cancer cells in vivo with minimal damage to surrounding tissue and fewer side effects than chemotherapy. This promising new treatment strategy could expand the current use of photodynamic therapies to access deep-set cancer tumors. [More]
Penn Medicine announces recipients of new Basser External Research Grant Program

Penn Medicine announces recipients of new Basser External Research Grant Program

The University of Pennsylvania's Basser Research Center for BRCA has announced $6.9 million to research teams both at Penn and at five other institutions across the United States, aimed at advancing the care of patients living with BRCA1 and BRCA2 mutations through multi-disciplinary collaboration. [More]
New technique for treating eye cancer retinoblastoma

New technique for treating eye cancer retinoblastoma

Doctors at Cincinnati Children's Hospital Medical Center have developed a new technique for treating the eye cancer retinoblastoma to improve the odds for preventing eye loss, blindness or death in children with advanced forms of the disease. [More]
Gene in soil-dwelling amoeba may hold key to isolating cancerous tumors

Gene in soil-dwelling amoeba may hold key to isolating cancerous tumors

The dirt in your backyard may hold the key to isolating cancerous tumors and to potential new treatments for a host of cancers. [More]
Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Eisai, Helsinn Group announce FDA approval of AKYNZEO for prevention of CINV

Helsinn Group and Eisai Inc. announced today that the Food and Drug Administration (FDA) approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. [More]
NCCN publishes 20th annual editions of NCCN Guidelines for Colon and Rectal Cancers

NCCN publishes 20th annual editions of NCCN Guidelines for Colon and Rectal Cancers

The National Comprehensive Cancer Network has published the 20th annual editions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon and Rectal Cancers, two of the eight original NCCN Guidelines published in November 1996. [More]
Discovery may provide new therapeutic avenue to target autophagy in tumors

Discovery may provide new therapeutic avenue to target autophagy in tumors

No matter what type of chemotherapy you attack a tumor with, many cancer cells resort to the same survival tactic: They start eating themselves. [More]
VAL-083 drug compound shows promise against non-small cell lung cancer

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai. [More]
CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors. [More]
Tel Aviv University researcher advances novel strategy to fight cancer by shoring up the immune system

Tel Aviv University researcher advances novel strategy to fight cancer by shoring up the immune system

Two years ago, Prof. Eshel Ben-Jacob of Tel Aviv University's School of Physics and Astronomy and Rice University's Center for Theoretical Biological Physics made the startling discovery that cancer, like an enemy hacker in cyberspace, targets the body's communication network to inflict widespread damage on the entire system. [More]